ArticleBlood cancer journal2022
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2023Pooled it
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.The New England journal of medicine · 2022Trial
- Evolution of real-world frontline treatment patterns in multiple myeloma.Blood advances · 2026Article
- Next-generation sequencing-based high-risk genomic stratification in multiple myeloma.Translational cancer research · 2026Article
- Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.Clinical lymphoma, myeloma & leukemia · 2026Article
- Trends in renal failure-related mortality among U.S. multiple myeloma patients aged ≥ 45 years, 1999-2023: analysis of CDC data.Scientific reports · 2026Article
- Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.Cancers · 2026Article
- Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications.Leukemia & lymphoma · 2026Review
- Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.Blood cancer journal · 2025Article
- Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.Blood cancer journal · 2025Article
- Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.British journal of haematology · 2025Article
- Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.Future oncology (London, England) · 2025Article
- Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.Cancer causes & control : CCC · 2025Article
- Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2025Article
- Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma.Blood advances · 2025Article
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.Blood cancer journal · 2024Article
- Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center.Transplantation and cellular therapy · 2024Article
- Disparities in Musculoskeletal Oncology.Current reviews in musculoskeletal medicine · 2024Review
- Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action.Journal of the advanced practitioner in oncology · 2024Review
- Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.JCO oncology practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
We assessed differences in survival between non-Hispanic black (NHB) and non-Hispanic white (NHW) patients with multiple myeloma (MM), and the sequential effects of patient characteristics, and diagnosis and treatment-related factors on the survival disparity using data from 3319 NHB and 20,831 NHW MM patients in the SEER-Medicare (1999-2017) database. Four sets of 3319 NHWs were matched sequentially to the same set of 3319 NHBs, based on demographics (age, sex, year of diagnosis, marital status, and SEER site), socioeconomic status (SES, demographics plus SES), presentation factors (SES variables plus comorbidity), and treatment factors (presentation variables plus antimyeloma therapies). We found NHBs were less likely to receive treatment than NHWs even among patients matched for demographics, SES, and comorbidities. The absolute difference in 5-year survival between NHBs and NHWs was not significant in the demographics match (0.6%; P = 0.30) and remained non-significant after matching for SES (1.4%, P = 0.17). When matching for presentation, NHBs had significantly longer 5-year survival than NHWs (absolute difference = 3.8%, P = 0.003). Additional matching on treatment-related factors further enlarged the racial difference in 5-year survival to 4.6% (P < 0.001). Our findings reinforce the importance of equitable access to effective treatment modalities to further improve the survival of NHB patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.